PPAN

Summary

PPAN (peter pan homolog, HGNC:9227) is a protein-coding gene on chromosome 19p13.2, encoding Suppressor of SWI4 1 homolog (Q9NQ55). May have a role in cell growth. It is a common-essential gene (DepMap: required in 99.8% of cancer cell lines).

The protein encoded by this gene is an evolutionarily conserved protein similar to yeast SSF1 as well as to the gene product of the Drosophila gene peter pan (ppan). SSF1 is known to be involved in the second step of mRNA splicing. Both SSF1 and ppan are essential for cell growth and proliferation. Exogenous expression of this gene was reported to reduce the anchorage-independent growth of some tumor cells. Read-through transcription of this gene with P2RY11/P2Y(11), an adjacent downstream gene that encodes an ATP receptor, has been found. These read-through transcripts are ubiquitously present and up-regulated during granulocyte differentiation.

Source: NCBI Gene 56342 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 26 total — 1 pathogenic
• Cancer dependency (DepMap): dependent in 99.8% of screened cell lines (common-essential)
• MANE Select transcript: NM_020230

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:9227
Approved symbol	PPAN
Name	peter pan homolog
Location	19p13.2
Locus type	gene with protein product
Status	Approved
Aliases	SSF1, SSF2, SSF, BXDC3
Ensembl gene	ENSG00000130810
Ensembl biotype	protein_coding
OMIM	607793
Entrez	56342

Gene structure

Transcript identifiers

Ensembl transcripts: 16 — 13 protein_coding, 3 retained_intron

ENST00000253107, ENST00000393793, ENST00000430370, ENST00000444703, ENST00000446223, ENST00000466025, ENST00000468881, ENST00000486482, ENST00000891444, ENST00000891445, ENST00000891446, ENST00000931026, ENST00000931027, ENST00000969248, ENST00000969249, ENST00000969250

RefSeq mRNA: 3 — MANE Select: NM_020230 NM_001346139, NM_001346141, NM_020230

CCDS: CCDS12225, CCDS86698

Canonical transcript exons

ENST00000253107 — 12 exons

Exon	Start	End
ENSE00001374030	10106362	10106412
ENSE00001704453	10110945	10112012
ENSE00003472144	10110123	10110246
ENSE00003483583	10110697	10110866
ENSE00003495152	10110485	10110614
ENSE00003535794	10107964	10108134
ENSE00003568439	10107505	10107606
ENSE00003569362	10106501	10106671
ENSE00003608310	10107804	10107854
ENSE00003627655	10110324	10110402
ENSE00003681380	10109631	10109707
ENSE00003693932	10109913	10110020

Expression profiles

Bgee: expression breadth ubiquitous, 239 present calls, max score 94.99.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 2.8464 / max 50.0734, expressed in 1340 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
173732	39.9666	1809
173733	1.6392	1034
173734	0.7678	368
208683	0.4395	216

Top tissues by expression

271 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sural nerve	UBERON:0015488	94.99	gold quality
granulocyte	CL:0000094	91.69	gold quality
mucosa of transverse colon	UBERON:0004991	90.73	gold quality
lower esophagus mucosa	UBERON:0035834	90.16	gold quality
tongue squamous epithelium	UBERON:0006919	89.86	silver quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	89.80	gold quality
gastrocnemius	UBERON:0001388	89.78	gold quality
esophagus mucosa	UBERON:0002469	89.58	gold quality
parotid gland	UBERON:0001831	89.26	gold quality
skin of leg	UBERON:0001511	89.13	gold quality
skin of abdomen	UBERON:0001416	89.12	gold quality
left uterine tube	UBERON:0001303	89.10	gold quality
apex of heart	UBERON:0002098	88.72	gold quality
muscle of leg	UBERON:0001383	88.69	gold quality
gingival epithelium	UBERON:0001949	88.54	gold quality
spleen	UBERON:0002106	88.43	gold quality
esophagus	UBERON:0001043	88.12	gold quality
body of stomach	UBERON:0001161	87.89	gold quality
body of pancreas	UBERON:0001150	87.78	gold quality
vermiform appendix	UBERON:0001154	87.58	gold quality
ectocervix	UBERON:0012249	87.57	gold quality
muscle layer of sigmoid colon	UBERON:0035805	87.57	gold quality
pancreatic ductal cell	CL:0002079	87.52	silver quality
transverse colon	UBERON:0001157	87.44	gold quality
omental fat pad	UBERON:0010414	87.40	gold quality
right ovary	UBERON:0002118	87.36	gold quality
peritoneum	UBERON:0002358	87.36	gold quality
left ovary	UBERON:0002119	87.13	gold quality
right lobe of liver	UBERON:0001114	87.06	gold quality
small intestine Peyer’s patch	UBERON:0003454	87.04	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.15
E-MTAB-6911	no	284.16
E-MTAB-6524	no	155.39

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

1 targeting PPAN, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4277	98.34	67.17	1323

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 99.8% of screened cell lines, common-essential.

Literature-anchored findings (GeneRIF, showing 5)

• The functional analysis of the Drosophila homolog. [LH] (PMID:10359593)
• a novel nucleolar stress-response pathway involving PPAN, NPM, and BAX to guarantee cell survival in a p53-independent manner. (PMID:25759387)
• data underline the notion that the PPAN-mediated, p53-independent nucleolar stress response has multiple facets. (PMID:30716409)
• The study uncovers that PPAN knockdown is linked to mitochondrial damage and stimulates autophagy. (PMID:31416196)
• An SNP reducing SNORD105 and PPAN expression decreases the risk of hepatocellular carcinoma in a Chinese population. (PMID:34741342)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	ppan	ENSDARG00000022232
mus_musculus	Ppan	ENSMUSG00000004100
rattus_norvegicus	Ppan	ENSRNOG00000020608
drosophila_melanogaster	ppan	FBGN0010770
caenorhabditis_elegans	lpd-6	WBGENE00003062

Protein

Protein identifiers

Suppressor of SWI4 1 homolog — Q9NQ55 (reviewed: Q9NQ55)

Alternative names: Brix domain-containing protein 3, Peter Pan homolog

All UniProt accessions (5): Q9NQ55, A8MV53, C9J3W3, C9JHF7, H7C446

UniProt curated annotations — full annotation on UniProt →

Function. May have a role in cell growth.

Subcellular location. Nucleus. Nucleolus.

Tissue specificity. Widely expressed.

Miscellaneous. A chimeric transcript, characterized by the first third of PPAN exon 12 joined to P2RY11 exon 2, has been detected. It is possibly produced by trans-splicing. The chimeric transcript is widely expressed and can be induced by retinoic acid during the granulocytic differentiation of the HL-60 cell line. The resulting chimeric protein shows a much lower activity than the non-chimeric P2RY11 gene product, but qualitatively indistinguishable.

Isoforms (3)

UniProt ID	Names	Canonical?
Q9NQ55-1	1	yes
Q9NQ55-2	2
Q9NQ55-3	3

RefSeq proteins (3): NP_001333068, NP_001333070, NP_064615* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR007109	Brix	Domain
IPR045112	PPAN-like	Family

Pfam: PF04427

UniProt features (18 total): compositionally biased region 6, modified residue 4, splice variant 2, sequence variant 2, chain 1, domain 1, sequence conflict 1, region of interest 1

Structure

Experimental structures (PDB)

4 structures.

PDB	Method	Resolution (Å)
8FKQ	ELECTRON MICROSCOPY	2.76
8FKP	ELECTRON MICROSCOPY	2.85
8FKS	ELECTRON MICROSCOPY	2.88
8FKR	ELECTRON MICROSCOPY	2.89

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9NQ55-F1	72.84	0.25

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (4): 240, 359, 438, 238

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 146 (showing top): GOBP_RIBOSOME_BIOGENESIS, SHEPARD_CRASH_AND_BURN_MUTANT_UP, MUELLER_PLURINET, CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_1, GOBP_MATURATION_OF_LSU_RRNA, HESS_TARGETS_OF_HOXA9_AND_MEIS1_UP, BROWN_MYELOID_CELL_DEVELOPMENT_DN, SPIELMAN_LYMPHOBLAST_EUROPEAN_VS_ASIAN_UP, MARCINIAK_ER_STRESS_RESPONSE_VIA_CHOP, BONOME_OVARIAN_CANCER_POOR_SURVIVAL_DN, SARTIPY_NORMAL_AT_INSULIN_RESISTANCE_UP, GOBP_RIBONUCLEOPROTEIN_COMPLEX_BIOGENESIS, GOBP_RIBOSOMAL_LARGE_SUBUNIT_BIOGENESIS, IVANOVA_HEMATOPOIESIS_EARLY_PROGENITOR, CUI_TCF21_TARGETS_2_UP

GO Biological Process (2): maturation of LSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA) (GO:0000463), rRNA processing (GO:0006364)

GO Molecular Function (2): RNA binding (GO:0003723), rRNA binding (GO:0019843)

GO Cellular Component (3): nucleus (GO:0005634), nucleolus (GO:0005730), preribosome, large subunit precursor (GO:0030687)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
maturation of LSU-rRNA	1
RNA processing	1
rRNA metabolic process	1
ribosome biogenesis	1
nucleic acid binding	1
RNA binding	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
intracellular membraneless organelle	1
preribosome	1

Protein interactions and networks

STRING

1882 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PPAN	P2RY11	Q96G91	894
PPAN	P2RY4	P51582	826
PPAN	EIF3G	O75821	781
PPAN	P2RY1	P47900	645
PPAN	PPCDC	Q96CD2	577
PPAN	RPF2	Q9H7B2	559
PPAN	NOL9	Q5SY16	552
PPAN	SRSF1	Q07955	551
PPAN	DDX51	Q8N8A6	484
PPAN	PES1	O00541	482
PPAN	PANK1	Q8TE04	480
PPAN	PPCS	Q9HAB8	478
PPAN	RRP15	Q9Y3B9	469
PPAN	URB1	O60287	464
PPAN	SCEL	O95171	463

IntAct

192 interactions, top by confidence:

A	B	Type	Score
PIK3CB	PIK3R2	psi-mi:“MI:0914”(association)	0.860
PTK2	TGFB1I1	psi-mi:“MI:0914”(association)	0.680
NPM1	NVL	psi-mi:“MI:0914”(association)	0.610
NPM1	MPHOSPH10	psi-mi:“MI:0914”(association)	0.610
RPL28	MAGEB2	psi-mi:“MI:0914”(association)	0.560
N	NOP56	psi-mi:“MI:0914”(association)	0.530
RPS3	ZNF316	psi-mi:“MI:0914”(association)	0.530
RPL37A	MPHOSPH10	psi-mi:“MI:0914”(association)	0.530
PPAN	PPM1G	psi-mi:“MI:0914”(association)	0.530
PRR11	NVL	psi-mi:“MI:0914”(association)	0.530
RPL18A	RRP8	psi-mi:“MI:0914”(association)	0.530
RPL30	RRP8	psi-mi:“MI:0914”(association)	0.530
MAGEB2	GTPBP10	psi-mi:“MI:0914”(association)	0.530
PTGES3	AIP	psi-mi:“MI:0914”(association)	0.530
RPS2	MPHOSPH10	psi-mi:“MI:0914”(association)	0.530
NHSL3	NCK2	psi-mi:“MI:0914”(association)	0.530
RPL7A	NVL	psi-mi:“MI:0914”(association)	0.530
DAXX	TNRC18	psi-mi:“MI:0914”(association)	0.530
JUN	TPM3	psi-mi:“MI:0914”(association)	0.350
NP	IPO5	psi-mi:“MI:0914”(association)	0.350
RRP1B	ZNF785	psi-mi:“MI:0914”(association)	0.350
MKI67	ARHGAP10	psi-mi:“MI:0914”(association)	0.350
		psi-mi:“MI:0914”(association)	0.350
Prdm16	ESYT2	psi-mi:“MI:0914”(association)	0.350
Mecom	ESYT2	psi-mi:“MI:0914”(association)	0.350
SCARB2	PLEKHG3	psi-mi:“MI:0914”(association)	0.350
ESR1	ESYT2	psi-mi:“MI:0914”(association)	0.350
CAND1	GTPBP10	psi-mi:“MI:0914”(association)	0.350

BioGRID (431): PPAN (Affinity Capture-MS), PPAN (Affinity Capture-MS), PPAN-P2RY11 (Affinity Capture-MS), PPAN-P2RY11 (Affinity Capture-MS), PPAN-P2RY11 (Affinity Capture-MS), PPAN-P2RY11 (Affinity Capture-MS), PPAN-P2RY11 (Affinity Capture-MS), PPAN-P2RY11 (Affinity Capture-MS), PPAN-P2RY11 (Affinity Capture-MS), PPAN-P2RY11 (Affinity Capture-MS), PPAN-P2RY11 (Affinity Capture-MS), PPAN-P2RY11 (Affinity Capture-MS), PPAN (Reconstituted Complex), PPAN (Affinity Capture-MS), PPAN (Affinity Capture-MS)

ESM2 similar proteins: A0A0G2JV04, D4A1F2, F1MF74, F1QWK4, O54935, O75038, O94851, P18858, P18887, P37913, P41111, P49916, P51432, P51892, P58404, P78563, P97386, Q01970, Q12851, Q1HFZ0, Q3T058, Q3TX08, Q58DG1, Q5HZH2, Q5REM3, Q60596, Q61211, Q61749, Q63186, Q641W2, Q7ZU92, Q8BMI3, Q8BML1, Q8CG07, Q91YU8, Q92918, Q96T60, Q99JE6, Q9D2Q2, Q9ESZ0

Diamond homologs: O14206, P38789, Q12153, Q54N44, Q5REM3, Q91YU8, Q9ASU7, Q9NQ55, Q9VDE5

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 222 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Peptide chain elongation	32	27.4×	3e-36
Viral mRNA Translation	32	27.4×	3e-36
PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA	32	27.1×	4e-36
Selenocysteine synthesis	32	26.0×	1e-35
Eukaryotic Translation Termination	32	26.0×	1e-35
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)	32	25.5×	2e-35
ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA	32	25.5×	2e-35
Eukaryotic Translation Initiation	12	25.0×	7e-13

GO biological processes:

GO term	Partners	Fold	FDR
negative regulation of DNA recombination	6	34.0×	2e-06
cytoplasmic translation	35	32.7×	1e-41
chromosome condensation	6	25.5×	1e-05
ribosomal large subunit biogenesis	8	17.9×	2e-06
translation	33	17.1×	8e-29
ribosomal small subunit biogenesis	13	14.9×	8e-10
negative regulation of proteasomal ubiquitin-dependent protein catabolic process	6	12.2×	8e-04
rRNA processing	16	11.4×	2e-10

Disease & clinical

Clinical variants and AI predictions

ClinVar

26 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	17
Likely benign	5
Benign	0

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
146077	GRCh38/hg38 19p13.2(chr19:9735443-11228001)x1	Pathogenic

SpliceAI

1699 predictions. Top by Δscore:

Variant	Effect	Δscore
19:10106370:G:GT	donor_gain	1.0000
19:10106408:G:GT	donor_gain	1.0000
19:10106408:GGAGG:G	donor_gain	1.0000
19:10106409:G:T	donor_gain	1.0000
19:10106409:GAGG:G	donor_gain	1.0000
19:10106409:GAGGG:G	donor_gain	1.0000
19:10106410:A:T	donor_gain	1.0000
19:10106411:GG:G	donor_gain	1.0000
19:10106412:GG:G	donor_gain	1.0000
19:10106413:G:GC	donor_loss	1.0000
19:10106414:T:A	donor_loss	1.0000
19:10106496:CGCA:C	acceptor_loss	1.0000
19:10106497:GCAGT:G	acceptor_loss	1.0000
19:10106498:CA:C	acceptor_loss	1.0000
19:10106499:A:AG	acceptor_gain	1.0000
19:10106500:G:GC	acceptor_gain	1.0000
19:10106500:GT:G	acceptor_gain	1.0000
19:10106500:GTCCC:G	acceptor_gain	1.0000
19:10106668:GCAG:G	donor_gain	1.0000
19:10106671:GGT:G	donor_loss	1.0000
19:10106672:G:C	donor_loss	1.0000
19:10106672:G:GG	donor_gain	1.0000
19:10107493:T:A	acceptor_gain	1.0000
19:10107493:T:TA	acceptor_gain	1.0000
19:10107497:A:AG	acceptor_gain	1.0000
19:10107498:T:G	acceptor_gain	1.0000
19:10107503:A:AG	acceptor_gain	1.0000
19:10107503:AG:A	acceptor_gain	1.0000
19:10107504:G:GA	acceptor_gain	1.0000
19:10107504:GG:G	acceptor_gain	1.0000

AlphaMissense

3096 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:10110328:G:A	G276D	0.998
19:10109701:G:C	R195P	0.997
19:10110327:G:C	G276R	0.996
19:10110331:C:A	P277Q	0.996
19:10110334:G:C	R278P	0.995
19:10110343:T:C	L281P	0.995
19:10109652:C:A	R179S	0.994
19:10109653:G:C	R179P	0.994
19:10110331:C:G	P277R	0.994
19:10110236:G:C	R271P	0.993
19:10110328:G:T	G276V	0.993
19:10106580:T:A	V33E	0.992
19:10107545:C:A	A77D	0.992
19:10109655:T:C	C180R	0.992
19:10109662:T:C	L182P	0.991
19:10110229:G:C	A269P	0.991
19:10108040:T:C	L140P	0.990
19:10109914:A:C	S198R	0.990
19:10109916:C:A	S198R	0.990
19:10109916:C:G	S198R	0.990
19:10110233:T:A	V270E	0.990
19:10110239:T:C	L272P	0.990
19:10106634:G:C	R51P	0.989
19:10107560:T:A	V82D	0.989
19:10108046:T:A	V142E	0.989
19:10109706:T:G	Y197D	0.989
19:10110327:G:T	G276C	0.989
19:10107847:T:A	V112D	0.988
19:10108040:T:A	L140H	0.988
19:10110239:T:A	L272H	0.988

dbSNP variants (sampled 300 via entrez): RS1000302985 (19:10109677 C>G), RS1000836315 (19:10107201 G>T), RS1000867060 (19:10105519 A>G), RS1001462745 (19:10109292 G>A,C,T), RS1001777895 (19:10107007 T>A), RS1001914776 (19:10106782 A>G), RS1002304897 (19:10106455 C>A,T), RS1002810752 (19:10108551 T>C), RS1003260955 (19:10105247 G>A), RS1003399374 (19:10112297 C>A,T), RS1003619151 (19:10112377 G>C), RS1003777981 (19:10108865 T>C), RS1003913797 (19:10109469 C>A), RS1003961713 (19:10105328 A>C), RS1004113751 (19:10111622 CTG>C)

Disease associations

OMIM: gene MIM:607793 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): narcolepsy-cataplexy syndrome (MONDO:0016158)

Orphanet (1): Narcolepsy type 1 (Orphanet:2073)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

36 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Estradiol	increases expression	2
Valproic Acid	decreases expression, increases methylation	2
Cyclosporine	increases expression	2
FR900359	increases phosphorylation	1
beauvericin	decreases expression	1
alpha phellandrene	decreases expression	1
deoxynivalenol	increases expression	1
sodium arsenite	decreases expression	1
gossypol acetic acid	increases expression	1
CGP 52608	affects binding, increases reaction	1
abrine	increases expression	1
NSC 689534	decreases expression, affects binding	1
Temozolomide	increases expression	1
Air Pollutants	affects expression, increases abundance	1
Arsenic	affects methylation	1
Benzo(a)pyrene	increases methylation	1
Cisplatin	decreases expression	1
Copper	affects binding, decreases expression	1
Cycloheximide	increases expression, affects cotreatment	1
Enzyme Inhibitors	decreases activity, increases O-linked glycosylation	1
Ethyl Methanesulfonate	decreases expression	1
Formaldehyde	decreases expression	1
Hydrogen Peroxide	affects expression	1
Methyl Methanesulfonate	decreases expression	1
Nickel	increases expression	1
Ozone	affects expression, increases abundance	1
Ribonucleotides	affects binding	1
Silicon Dioxide	increases expression	1
Smoke	decreases expression	1
Testosterone	increases expression	1

Clinical trials (associated diseases)

49 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT02637076	PHASE4	COMPLETED	Xyrem and Brain Dopamine in Narcolepsy
NCT01800045	PHASE3	COMPLETED	Pitolisant to Assess Weekly Frequency of Cataplexy Attacks and EDS in Narcoleptic Patients (HARMONY CTP)
NCT02221869	PHASE3	COMPLETED	A Multicenter Study of the Efficacy and Safety of Xyrem With an Open- Label Pharmacokinetic Evaluation and Safety Extension in Pediatric Subjects With Narcolepsy With Cataplexy
NCT02611687	PHASE3	COMPLETED	Efficacy and Safety of Pitolisant in Pediatric Narcoleptic Patients With or Without Cataplexy, Double-blind Study Followed by a Prolonged Open-label Period
NCT03030599	PHASE3	COMPLETED	A Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy
NCT05914194	PHASE3	NOT_YET_RECRUITING	A Eight-Week Study of NLS-2 (Mazindol Extended Release) in Participants With Narcolepsy Type 1
NCT06470828	PHASE3	COMPLETED	A Study of TAK-861 for the Treatment of Narcolepsy Type 1
NCT06505031	PHASE3	COMPLETED	A Study of TAK-861 in People With Narcolepsy Type 1
NCT07363720	PHASE3	RECRUITING	A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy
NCT07455383	PHASE3	RECRUITING	A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1
NCT07540897	PHASE3	RECRUITING	A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)
NCT04026958	PHASE2	COMPLETED	Clarithromycin Mechanisms in Hypersomnia Syndromes
NCT04096560	PHASE2	TERMINATED	A Study of TAK-994 in Adults With Type 1 and Type 2 Narcolepsy
NCT04820842	PHASE2	TERMINATED	A Study of TAK-994 in Adults With Narcolepsy
NCT05055024	PHASE2	COMPLETED	An Open Label Study of NLS-2 (Mazindol Extended Release) in Subjects With Narcolepsy
NCT05687903	PHASE2	COMPLETED	A Study of TAK-861 in Participants With Narcolepsy Type 1
NCT06358950	PHASE2	COMPLETED	A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201)
NCT06752668	PHASE2	RECRUITING	A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia
NCT06809803	PHASE2	RECRUITING	Extended-release Sodium Oxybate in Children
NCT07096674	PHASE2	RECRUITING	A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia
NCT00345800	PHASE1	COMPLETED	Exploratory Clinical Study to Evaluate Sodium Oxybate (Xyrem) on Potential Endocrine Changes
NCT06462404	PHASE1	COMPLETED	A Study to Evaluate the Efficacy, Safety, and Tolerability of E2086 Compared to Placebo and Active Comparator in Adult Participants With Narcolepsy Type 1
NCT07584434	PHASE1	NOT_YET_RECRUITING	A Phase 1, First-in-human Study of VX-433
NCT05816382	PHASE2/PHASE3	RECRUITING	A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions
NCT06767683	PHASE2/PHASE3	RECRUITING	A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia
NCT07598708	PHASE2/PHASE3	NOT_YET_RECRUITING	A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence
NCT03433131	Not specified	NO_LONGER_AVAILABLE	Expanded Access Program to Provide Treatment With Pitolisant to Adult Patients in the U.S. With Excessive Daytime Sleepiness Associated With Narcolepsy With or Without Cataplexy
NCT04306952	Not specified	COMPLETED	Awareness and Self-Compassion Enhancing Narcolepsy Treatment
NCT04419792	Not specified	SUSPENDED	‘A Profile of Physical Performance Variables in an Out-patient Adult Population With Narcolepsy’
NCT04445129	Not specified	COMPLETED	Wake and Sleep State Transitions on a Portable Electroencephalogram (EEG) Device in Narcolepsy Type 1 (NT1) and Healthy Participants
NCT04483310	Not specified	UNKNOWN	Meditation-Relaxation (MR Therapy) for Sleep Paralysis.
NCT05314556	Not specified	COMPLETED	Group Psychotherapy in Narcolepsy Type 1
NCT05375890	Not specified	COMPLETED	Clinical and Neurophysiological Characteristics of Narcolepsy
NCT05460052	Not specified	COMPLETED	Evaluation of the Effectiveness of a Physical Activity Program on the Severity of Narcolepsy
NCT05709873	Not specified	COMPLETED	Narcolepsy Nightmare Study
NCT05967832	Not specified	UNKNOWN	Contribution of 7 Tesla MRI of the Hypothalamus in the Diagnosis of Type 1 Narcolepsy
NCT05983731	Not specified	UNKNOWN	A Pilot Observational Study to Assess the Ability of Continuous ‘Home’ EEG to Accurately Diagnose Narcolepsy and Demonstrate Response to Treatment
NCT06241911	Not specified	COMPLETED	Transcutaneous Auricular Vagus Nerve Stimulation in Patients With Narcolepsy Type 1
NCT06251063	Not specified	COMPLETED	Improving Social Relationships for Adolescents With Central Disorders of Hypersomnolence
NCT06292598	Not specified	RECRUITING	Bacterial Translocation and Gut Microbiota in Type 1 Narcolepsy Patients Versus a Control Population